Resurge reports early AUA 2026 BPH data for IPDE platform
Bottom line
Resurge Therapeutics said it will present positive clinical results at the American Urological Association’s 2026 annual meeting for its intraprostatic drug elution, or IPDE, platform in benign prostatic hyperplasia. In a transperineal dose-escalation study of 20 men, the company reported a 15-point average improvement in International Prostate Symptom Score at one year after a single treatment, with about a 4 mL/s gain in maximum urinary flow rate and no serious drug- or procedure-related adverse events. In a separate transrectal feasibility study of 11 men, Resurge reported a 15-point mean IPSS improvement as early as one month, sustained through at least six months, a 4.1 mL/s increase in urinary flow, and a 23% reduction in prostate volume at six months. The platform uses paclitaxel-eluting bioabsorbable implants and is being positioned as a one-time, office-based treatment for lower urinary tract symptoms secondary to BPH. (prnewswire.com)
Why it matters: For veterinary professionals, this is mainly a translational signal rather than a practice-changing development. Companion animals, especially intact male dogs, also develop prostatic disease, but BPH management in veterinary medicine differs substantially from human care. Even so, the Resurge data add to broader interest in localized, office-based drug delivery approaches that aim to reduce reliance on chronic oral therapy and more invasive procedures. That lands at a moment when the AUA’s newly updated 2026 BPH guideline is emphasizing individualized care and reflecting continued expansion of minimally invasive treatment options. (globenewswire.com)
What to watch: Watch for the full AUA 2026 presentation details, longer-term follow-up, and any FDA-facing development plans beyond these early studies. (prnewswire.com)
Resurge Therapeutics is using AUA 2026 to showcase updated clinical data for its IntraProstatic Drug Elution platform, a localized drug-delivery approach for benign prostatic hyperplasia that aims to sit between chronic oral medication and more invasive procedural care. In a May 14 press release, the San Jose-based, clinical-stage urology company said two studies found meaningful improvements in symptom scores and urinary flow after a single treatment, with no serious drug- or procedure-related adverse events reported. (prnewswire.com)
The company has been building this story for at least a year. At AUA 2025, Resurge reported six-month first-in-human results from its initial dose cohort, including an average 11-point improvement in symptom score and a 5 mL/s improvement in urinary flow, and said it planned to work with FDA on further development. The new AUA 2026 update extends that narrative with data from both transperineal and transrectal delivery approaches, suggesting the platform may be adaptable across procedural workflows while keeping the treatment in an office-based setting. (prnewswire.com)
The headline numbers are notable for an early-stage program. In the transperineal dose-escalation study, which enrolled 20 men, Resurge reported a 15-point average improvement in IPSS at one year, roughly a 4 mL/s increase in Qmax, and clinically significant symptom improvement in 80% of participants. In the separate transrectal feasibility study of 11 men, mean IPSS improved by 15 points as early as one month and remained improved through at least six months, with Qmax up 4.1 mL/s and prostate volume down 23% at six months. Across both studies, the company said pain scores at discharge were minimal, adverse events were mild and transient, and there were no reported cases of de novo erectile dysfunction or systemic drug toxicity. (prnewswire.com)
The platform itself reflects a broader shift in BPH treatment toward localized, minimally invasive interventions. Resurge’s approach uses paclitaxel-eluting bioabsorbable implants placed directly into the prostate to drive what it describes as targeted remodeling. That puts it in the same broad innovation lane as other office-based BPH technologies, though with a different mechanism. Recent expert overviews in urology have highlighted growing interest in minimally invasive therapies that can preserve sexual function, shorten recovery, and better match treatment to patient anatomy and goals. Those reviews also underscore that the field is getting more crowded, with therapies such as water vapor ablation, prostatic urethral lift, temporary implantable devices, and paclitaxel-coated balloon systems all competing for a place in the care pathway. (prnewswire.com)
Independent expert reaction specific to Resurge’s data was limited in publicly available coverage as of May 15, 2026, which is common for conference-timed company announcements. Still, the broader clinical conversation is moving in a direction that may favor approaches like this if durability and safety hold up. The AUA’s updated 2026 guideline for lower urinary tract symptoms attributed to BPH emphasizes shared decision-making, individualized care, and newly available evidence across medical, minimally invasive, and surgical options. In that context, a one-time localized therapy with office-based potential could attract attention if later-stage evidence confirms the early signal. (globenewswire.com)
Why it matters: For veterinary professionals, this is not a directly practice-changing story, but it is relevant as a window into where localized drug-device combinations are heading. Veterinary medicine sees its own mix of chronic management challenges, procedural tradeoffs, and pet parent preferences around minimally invasive care. While canine prostatic disease is a different clinical category from human BPH in important ways, the strategic lesson is familiar: developers are trying to replace daily systemic treatment and higher-burden procedures with targeted, durable interventions delivered in lower-acuity settings. That trend is worth watching across species because it often shapes expectations in translational medicine, device design, and future companion-animal innovation. The caution, of course, is that these are still small, early studies announced by the company, not pivotal data. (prnewswire.com)
What to watch: The next signposts are the full AUA 2026 presentations, whether Resurge publishes these findings in a peer-reviewed setting, and whether the company outlines a formal regulatory path with FDA. Just as important will be longer follow-up to test durability, broader enrollment to clarify reproducibility, and comparative positioning against a fast-evolving BPH market that already includes several minimally invasive options with growing evidence bases. (prnewswire.com)